COMMUNIQUÉS West-GlobeNewswire

MBX Biosciences to Participate in June Investor Conferences
20/05/2025
CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Praxis Precision Medicines to Participate in Upcoming Conferences
20/05/2025
BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Expanded Partnership Increases Access to Unified, Intelligent Radiologist Desktops for Radiology Practices
20/05/2025
TAMPA, Fla. and WAYNE, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- NewVue, a leader in cloud-native radiology workflow solutions, today announced the expansion of its partnership with Konica Minolta Healthcare Americas, Inc [...]
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
20/05/2025
Subjects Demonstrated Marked Improvement of ADHD Symptoms at Week 5 New Drug Application on Schedule for this Summer CING CEO Shares Insights and Strategic Outlook on “ Unboxing Biotech ” Podcast KANSAS CITY, Kan., May [...]
Spectral AI Research Partner Using DeepView System Wins Best Research Project at the 2025 Education Awards
20/05/2025
DALLAS, May 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView ® System, which uses multi-spectral imaging and AI algorithms to [...]
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
20/05/2025
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
Enlivex Selected to Present at Israeli BioMed 2025 Conference
20/05/2025
Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “ [...]
Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis
20/05/2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the [...]
Devereux Georgia expands foster care services to Savannah
20/05/2025
Nonprofit to provide critical support for foster youth and families in the coastal Savannah region KENNESAW, Ga., May 20, 2025 (GLOBE NEWSWIRE) -- Devereux Advanced Behavioral Health Georgia today announced it is now [...]
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
20/05/2025
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s [...]
Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic
20/05/2025
The program, licensed exclusively to BMS, represents the third ADC candidate using the company’s proprietary Tubutecan technology to reach the clinic. MUNICH, GERMANY, May 20, 2025 – Tubulis today announced that the [...]
Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
20/05/2025
Two-part preclincal and clinical development programme launched to assess potential benefits of administering S-pindolol benzoate during and post-GLP-1 receptor agonist therapy to improve muscle mass, cardiac protection [...]
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer
20/05/2025
These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT ® ) significantly enhances the local effect of chemotherapy In the patients who had a response to chemotherapy, ACT-treated tumours showed a [...]
AB Science announces the successful completion of a EUR 1.8 million private placement
20/05/2025
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.8 MILLION PRIVATE PLACEMENT Paris, May 20, 2025, 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) announces [...]
AB Science annonce le succès d'un placement privé de 1,8 millions d'euros
20/05/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE D’ENVIRON 1,8 MILLION D’EUROS Paris, 20 mai 2025, 8h AB Science S.A. (la “ Société ” ou “ AB Science ”, Euronext – FR0010557264 – AB) annonce [...]
CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
20/05/2025
Press Release CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval The [...]
CROSSJECT prépare le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 5 millions d’euros en préparation des activités commerciales et de production liées à l’approbation EUA
20/05/2025
Communiqué de presse CROSSJECT prépare le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 5 millions d’euros en préparation des activités commerciales [...]
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
20/05/2025
Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections [...]
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
20/05/2025
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC Antibody Formats Towards Clinical Studies VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and [...]

Pages